Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

NeuroReport

Volumn 9, Issue 17, 1998, Pages 3897-3902

  Vollenweider, Franz X ^a   Vollenweider Scherpenhuyzen, Margreet F I ^a   Bäbler, Andreas ^a   Vogel, Helen ^a   Hell, Daniel ^a  

^a NONE

Author keywords

5 HT2A receptor; Haloperidol; Human; Ketanserin; Model psychosis; Psilocybin; Psychopathology; Risperidone; Schizophrenia; Visual manual delayed response task

Indexed keywords

HALOPERIDOL; KETANSERIN; PSILOCYBINE; PSYCHEDELIC AGENT; RISPERIDONE; SEROTONIN 2 AGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HALLUCINATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SEROTONIN RELEASE;

EID: 0032430801     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199812010-00024     Document Type: Article

References (25)

1. Gouzoulis-Mayfrank E, Hermle L, Thelen B et al. Pharmacopsychiatry 31 (Supp), 63-68 (1998).
2. Rummele W and Gnirss F, Schweiz Arch Neurol Psychiat 87, 365-385 (1961).
3. Vollenweider FX, Leenders KL, Scharfetter C et al. Neuropsychopharmacology 16, 357-372 (1997).
4. Spitzer M, Thimm M, Hermle L et al. Biol Psychiatry 39, 1055-1057 (1996).
5. Bowers MB and Freedman DX. Arch Gen Psychiatry 15, 240-248 (1966).
6. Heimann H. Psychiat Neurol 141, 69-100 (1991).
7. Fischman LG. Schizophrenia Bull 9, 73-94 (1983)
8. Ebmeier KP, Lawrie SM, Blackwood DH et al. J Neurol Neurosurg Psychiat 58, 452-456 (1995).
9. Hasler F, Bourquin D, Brenneisen R et al. Pharm Acts Helv 72, 175-184 (1997).
10. Abi-Dargham A, Laruelle M, Aghajanian GK et al. J Neuropsychiatry Clin Neurosci 9, 1-17 (1997).
11. Peroutka SJ. 5-hydroxytryptamine receptor interactions of D-lysergic acid diethylamide. In: Pletscher A and Ladewig D, eds. 50 Years of LSD. Current Status and Perspectives of Hallucinogens. New York: Parthenon Publishing, 1994: 19-26.
12. Sanders-Bush E, Burries KD and Knoth K. J Pharmacol Exp Ther 246, 924-928 (1988).
13. Titeler M, Lyon RA and Glennon RA. Psychopharmacology 94, 213-216 (1988).
14. Sipes TA and Geyer MA. Behav Pharmacol 6, 839-842 (1995).
15. Marek GJ and Aghajanian GK. J Pharmacol Exp Ther 278, 1373-1382 (1996).
16. Creese I, Burt DR and Snyder SH. Life Sci 17, 1715-1720 (1975).
17. Hoyer D and Schoeffter P. J Receptor Res 11, 197-214 (1991).
18. Meltzer HY. Schizophrenia Bull 17, 263-287 (1991).
19. Dittrich A, Psychological aspects of altered states of consciousness of the LSD type: measurements of their basic dimensions and prediction of individual differences. In: Pletscher A and Ladewig D, eds. 50 Years of LSD. Current Status and Perspectives of Hallucinogens. New York: Parthenon Publishing, 1994: 101-118.
20. Park S and Holzman PS. Arch Gen Psychiatry 49, 975-982 (1992).
21. Farde L, Nordström A-L, Wiesel F-A et al. Arch Gen Psychiatry 49, 538-544 (1992).
22. Nyberg S, Farde L, Eriksson L et al. Psychopharmacology 110, 265-272 (1993).
23. Gurevich EV and Joyce JN. Biol Psychiatry 42, 529-545 (1997).
24. Abramson HA, Rolo A and Stache J. J Neuropsychiatry 307-310 (1960).
25. Green MF, Marshall BDJ, Wirshing WC et al. Am J Psychiatry 154, 799-804 (1997).